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Abstract  
Contrarily to the Th-2-bias and eosinophil-dominated bronchial inflammation encountered in 
most asthmatics, other patients may exhibit neutrophil-predominant asthma sub-phenotypes along 
with Th-1 and Th-17 cells. However, the etiology of many neutrophil-dominated asthma sub-
phenotypes remains ill-understood, in part due to a lack of appropriate experimental models. To 
better understand the distinct immune-pathological features of eosinophilic versus neutrophilic 
asthma types, we developed an Ovalbumin (OVA)-based mouse model of neutrophil-dominated 
allergic pulmonary inflammation. Consequently, we probed for particular inflammatory 
signatures and checkpoints underlying the immune-pathology in this new model as well as in a 
conventional, eosinophil-dominated asthma model. Briefly, mice were OVA-sensitized using 
either aluminium hydroxide (alum) or Complete Freund´s (CFA)-adjuvants followed by OVA 
aerosol challenge. T-cell, granulocyte and inflammatory mediator profiles were determined along 
with alveolar macrophage genome-wide transcriptome profiling. In contrast to the Th-2-
dominated phenotype provoked by alum, OVA/CFA-adjuvant-based sensitization followed by 
allergen challenge elicited a pulmonary inflammation that was poorly controlled by 
dexamethasone, and in which Th-1 and Th-17 cells additionally participated. Analysis of the 
overall pulmonary and alveolar macrophage inflammatory mediator profiles revealed remarkable 
similarities between both models. Nevertheless, we observed pronounced differences in the IL-
12/IFN-γ axis and its control by IL-18 and IL-18 Binding Protein (BP), but also in macrophage 
arachidonic acid metabolism and expression of T-cell instructive ligands. These differential 
signatures, superimposed onto a generic inflammatory signature, denote distinctive inflammatory 
checkpoints potentially involved in orchestrating neutrophil-dominated asthma. Key words: 
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neutrophil-predominant asthma, allergic inflammation, alveolar macrophage, transcriptome, 
mouse models 
List of abbreviations 
APC= Antigen Presenting Cells 
Alum= Aluminium hydroxide 
AM= Alveolar Macrophages 
BAL= Broncho-Alveolar Lavage 
BP= Binding Protein 
CFA= Complete Freund´s (CFA)-Adjuvants 
DAMP= Danger Associated Molecular Patterns  
DAVID= Database for Annotation, Visualization and Integrated Discovery 
DC= Dendritic Cells 
Dex= dexamethasone 
EASE= Expression Analysis Systematic Explorer 
ELISA= Enzyme-Linked Immunosorbent Assay 
IL= Interleukin 
i.p.= intra-peritoneal 
KEGG= Kyoto Encyclopedia of Genes and Genomes 
LT= Leukotriene 
LX= Lipoxin 
HBSS= Hank’s Balanced Salt Solution 
H&E= Haematoxylin & Eosin 
HP= Hypersensitivity Pneumonitis  
MMP= Matrix Metalloproteinase 
OVA= Ovalbumin  
PBS= Phosphate-Buffered Saline 
PD-L= Programmed Death-Ligand 
PIR= Protein Information Resource 
PG= prostaglandin 
RT-qPCR= Reverse Transcriptase-quantitative Polymerase Chain Reaction 
SPF= Specific Pathogen Free 
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TCM= Tissue Culture Medium 
Th= T-helper cell 
Tc= cytotoxic T-cell 




Predominance of eosinophils in the airway wall and sputum constitutes a major pathological 
hallmark of persistent mild-to-moderate asthma, commonly defined as a chronic inflammation of 
the airways mediated by Th-2 cells and provoked in atopic individuals by repeated cycles of 
allergen inhalation (5, 18, 25). However, asthma is a heterogeneous disease and the emphasis on 
a Th-2-bias and eosinophilic bronchial inflammation fails to explain clinical observations in 
many cases in which patients present increased neutrophil cell counts in the airway lumen as a 
distinguishing trait, especially during acute exacerbations (13, 15, 21, 25). Furthermore, Th-1 
cells and cytotoxic T-cells (Tc), bronchiolitis and even alveolitis can often be detected in those 
patients (5, 9, 10, 18). Recently obtained data also show involvement of Th-17 cells in the patho-
physiology of neutrophil-predominant asthma, inducing the release of neutrophil-mobilizing 
cytokines from airway epithelial cells through IL-17 (1, 5, 9, 17, 28). The etiology of neutrophil-
type asthma forms is still ill-understood and precisely those patients with neutrophil-dominated 
inflammation often present with severe disease that appears resistant to conventional anti-
inflammatory glucocorticoid treatments (1, 12, 37). Moreover, experimental research is hampered 
by the current lack of suitable mouse models that mimic specific features of this condition (14). 
Remarkably, several aspects of neutrophilic asthma are prominently found in another type of 
allergic airway disease, namely hypersensitivity pneumonitis (HP) (16, 33, 49). Similarly to 
asthma, the HP-pathology is induced by exposure to airborne antigen in sensitized individuals. 
Th-1, Th-17 and Tc-cells are the main lymphocytic components in HP and were shown to 
mediate pathology in experimental HP-models (20, 43). Nevertheless, both allergic diseases 
differ in the nature of their causative agents: asthma-allergens are usually large proteins exerting 
enzymatic activity, whereas HP-eliciting allergens are often small proteins of microbial origin. 
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Differences in Danger Associated Molecular Patterns (DAMPs), either intrinsic to the allergen or 
coinciding at the time of allergen inhalation, are considered as critical in determining the type of 
ensuing allergic disease (6).   
These considerations made us speculate that a neutrophil-dominated allergic airway inflammation 
reminiscent of common neutrophil-predominant asthma sub-phenotypes could be raised in vivo as 
the result of an ‘accidental’ Th-1/Th-17-biased sensitization against antigens that intrinsically do 
not elicit danger signals necessary to sustain this type of response (6). In this study, we show that 
mice inhaling the model-allergen OVA develop allergic pulmonary inflammation with 
characteristics of neutrophil-predominant asthma if prior sensitization occurs in the presence of 
CFA, a potent Th-1/Th-17-skewing adjuvant commonly used in mouse models of HP (6, 20, 41, 
43). In addition, we exploited this new model of neutrophilic pulmonary inflammation as well as 
a conventional model of eosinophilic allergic pulmonary inflammation to seek by comparative 
expression analysis for distinct inflammatory signatures indicative of regulatory checkpoints 
controlling neutrophil-dominated asthma-like disease.  
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Methods 
Mouse models and collection of samples 
Female, 6-8 weeks-old C57BL/6 mice (Janvier, Le Genest St-Isle, France) were kept under 
Specific Pathogen Free (SPF)-conditions. Mice were immunized subcutaneously at day 0 with 20 
µg of grade V chicken egg OVA (Sigma-Aldrich, St.Louis, MO) in endotoxin-free Phosphate-
Buffered Saline (PBS; Lonza, Walkersville, MD), emulsified in 75 µl CFA (Sigma-Aldrich) + 25 
µl PBS (OVA/CFA model) or were immunized intra-peritoneally (i. p.) at days 0, 7 and 14 with 
20 µg of OVA, adsorbed on 1 mg Al(OH)3 (alum; Sigma-Aldrich) in PBS (OVA/alum model). 
At day 21 and 22, all mice (≥ 6 mice/group) were exposed to aerosols consisting of 0.1% 
(OVA/CFA) or 1% (OVA/alum) of grade III OVA (Sigma-Aldrich) in PBS. In experiments 
where Dex was used, mice received i.p. injections with 0, 1, or 2.5 mg/kg Dex (Sigma-Aldrich) 
in PBS 3h prior to OVA aerosol. Naïve mice received challenges with PBS alone. In some 
experiments, immunized but unchallenged mice were included. All experiments were done under 
conditions specified by law (European Directive and Belgian Royal Decree of November 14, 
1993) and reviewed and approved (LA140091/07-035) by the Institutional Ethics Committee on 
Experimental Animals. Twenty hours after the last OVA challenge, all mice were sacrificed for 
analysis. Broncho-Alveolar Lavage (BAL) was performed with HBSS (Hank’s Balanced Salt 
Solution, Invitrogen, Carlsbad, CA) supplemented with 10 mM EDTA. Supernatant from the first 
0.5 mL BAL fluid was stored at -20°C. After BAL, lungs were removed and put in 4% PFA (left 
lungs) or kept in Tissue Culture Medium (TCM; Invitrogen) on ice for homogenisation (right 
lungs) or snap-frozen in liquid nitrogen for total lung lysates. 
 
Cell isolation and flowcytometric/histological analysis of inflammation 
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Lung CD4 T-cells were isolated from pooled lungs, minced and digested with collagenase 
(Sigma-Aldrich). After removal of red blood cells, CD4 T-cells were isolated using biotinylated 
anti-CD4 (Pharmingen) and Dynal magnetic beads (Invitrogen). CD11chigh/autofluorescencehigh 
AM were isolated from pooled BAL cells by flowcytometric sorting using an Altra station 
(Beckman Coulter, Fullerton, CA). Labeling with anti-CD16/CD32 to block nonspecific binding 
and with anti-CD11c (Pharmingen) was performed at 4°C. Purity exceeded 95%.  
Flowcytometric analyses were performed on a FACSCalibur or LSR-II (BD Biosciences, San 
Jose, CA). The BAL cellular composition of individual mice was determined by analysis of 
surface expression of CD3ε, B220, CCR3, I-Ab and CD11c, or CD3ε, CD4, CD11b, CCR3, I-Ab 
and CD11c (45, 47). Expression of co-stimulatory ligands on alveolar macrophages (AM) or DC 
was analyzed on pooled BAL cells by surface expression of CD11c and I-Ab in combination with 
CD40, CD80, CD86, PD-L1 or PD-L2. Lung T-helper cell (Th) phenotypes were determined by 
analysis of surface expression of CD45, I-Ab, F4/80 and CD4, in combination with expression of 
IL-17, IL-4 and IFN-γ, or appropriate isotype controls. All antibodies were from Pharmingen 
(BD, San Diego, CA), except CCR3 (R&D Systems, Abingdon, UK). All labeling was performed 
at 4°C in the presence of anti-CD16/CD32 to block nonspecific binding. Gating strategies are 
provided in Suppl. Fig. 2 
Pulmonary inflammation was quantified on haematoxylin-eosin (H&E) stained 
paraformaldehyde-fixed paraffin-embedded lung sections.  
 
In vitro restimulation of lung CD4 T-cells 
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Pooled lungs were minced and digested with collagenase. After removal of red blood cells, lung 
cells were seeded in culture medium + 1µg/ml anti-CD3. After 1h, Golgi-Plug (Pharmingen) was 
added and cells were cultured for another 4h upon which they were harvested for flowcytometric 
analysis as described above. Cells were first stained for surface markers (CD45, I-Ab, F4/80, 
CD4), then fixed and permeabilized, and subsequently stained for intracellular cytokines (IL-17, 
IL-4, IFN-γ). 
 
Measurement of inflammatory mediators in BAL fluid 
Inflammatory mediators were measured in the first 0.5 mL fraction of the collected BAL fluid. 
Cytokines and chemokines were measured using the Bioplex suspension array system (Biorad) 
according to the manufacturer’s instructions, using recombinant cytokine standards (Biorad). 
MMP-9 and MMP-12 levels were determined by SDS-PAGE western blot analysis, using 
specific monoclonal antibodies (R&D Systems) and peroxidase-conjugated rabbit-anti-mouse 
IgG (Dako, Denmark) for detection. Active MMP-9 was analyzed by zymography on a SDS–
10% polyacrylamide gel + 1 mg/ml gelatin, detected as a lyses 95 kDa band. Culture medium 
from HT1080 cells served as internal standard. MMP-12 enzymatic activity was analyzed using 
the EnzoLyte 490 kit (AnaSpec, San Jose, CA, USA), optimized to detect MMP-12 activity in 
biological samples using a fluorescence quenched substrate (EDANS/DabcylPlusTM FRET 
peptide). MMP-12 purified enzyme used as positive control was purchased from Sigma (St Louis, 
Missouri, USA). Complement C3a levels were determined by Enzyme-Linked ImmunoSorbent 
Assay (ELISA), using anti-C3a clone I87-1162 (BD Pharmingen) for capture and biotinylated 
I87-419 clone (BD Pharmingen) for detection. Purified mouse C3a protein (BD Pharmingen) was 
used as standard. 




Total RNA was prepared using the Aurum total RNA mini kit (Biorad Hercules, CA). RNA 
quality was determined spectro-photometrically. For RT-qPCR, cDNA was prepared from 1 µg 
total RNA using oligo(dT), RNase inhibitor and SuperscriptII reverse transcriptase (all 
Invitrogen). PCR reactions were performed with the SybrGreen-I qPCR Core kit (Eurogentec, 
Liège, Belgium) and an iCycler (Biorad) instrument. Data were normalized for the expression 
levels of housekeeping genes (Ribosomal protein L13a and TATA box binding protein). 
Amplification specificity was confirmed by evaluation of the melting curves. n-Fold differences 
between samples were calculated using the 2-∆∆Ct method. The PCR primer pair sequences 
(Invitrogen) are provided in the Supplementary information. 
 
Transcriptome analysis 
RNA integrity was confirmed with the automated electrophoresis Experion System using the 
RNA StdSens Analysis Kit (Bio-Rad). 4 µg of total RNA, labeled using the GeneChip® 
Expression 3’ Amplification One-Cycle Target Labeling kit (Affymetrix, Santa Clara, CA), was 
hybridized to Genechip Mouse Genome 430A 2.0 (Affymetrix) according to the manufacturer’s 
instructions. Arrays were scanned with an Affymetrix/Hewlett-Packard GeneChip Scanner 3000 
7G (Palo Alto, CA). Data were generated with the MAS 5.0 algorithm included in Genechip 
Operating Software (GCOS). The naïve condition was set as baseline for pair-wise comparison 
with OVA-induced experimental conditions. The probe sets were filtered on Signal log ratio (>1 
for up regulated and <-1 for down regulated transcripts) and on p-value associated with the 
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Change status (<0.001 for up regulated probe sets, >0,999 for down regulated probe sets). The 
complete microarray data set can be consulted in the EBI Array Express Database 
(http://www.ebi.ac.uk/, accession number E-MEXP-2500). 
 
Statistical analysis 
Statistical significance on numbers of cells, cell composition, and mediator levels was determined 
with the Mann-Whitney U test (2 categorical variables) or Kruskall-Wallis test with post-hoc 
Bonferroni correction (> 2 categorical variables). Significant p-values were ranked as p<0.05 (*), 
p<0.01 (**) and p<0.001 (***). Data are represented as mean +/-SE or +/-SD (as indicated in the 
figures). 
 




1. Immunization with CFA predisposes mice to develop a neutrophilic asthma-like pulmonary 
inflammation that is poorly controlled by glucocorticoids 
To verify to what extent Th-1/Th-17-biased sensitization supports the development of  
neutrophilic asthma-like inflammation, C57BL/6 mice were systemically immunized against the 
model antigen OVA in the presence of CFA. Sensitization promoting an eosinophilic asthma-like 
immunopathology was generated by immunization against OVA in the presence of the Th-2-
skewing adjuvant alum. Thereafter, mice from both groups were challenged with nebulized OVA 
for two consecutive days. This then resulted in a significant cell infiltrate in the BAL fluid 
compared to naïve mice [Fig.1A]. 
 
Flowcytometric analysis of cell surface markers [Fig.1B] and histological analysis of H&E-
stained lung tissue sections [Fig.1C] revealed profound differences in the cellular infiltration 
between OVA/CFA- and OVA/alum-sensitized mice. As expected, the BAL fluid from the well-
established OVA/alum model contained mainly eosinophils (± 70%), AM/DC ((± 15%), 
lymphocytes (± 10%) and fewer neutrophils (< 10%). Histological analysis showed infiltration of 
eosinophils and monocytic cells almost exclusively around the peribronchiolar and perivascular 
areas. Contrarily, in the OVA/CFA-sensitized group, we found a substantial infiltration into the 
broncho-alveolar space of neutrophils, AM/DC  and lymphocytes (each ± 30%), and to a lesser 
extent eosinophils (± 10%) [Fig.1B]. Analysis of lung sections showed a strong infiltration of 
lymphocytes, monocytic cells and neutrophils around peribronchiolar and perivascular areas, 
although also a patchy interstitial infiltrate was observed [Fig.1C].  
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To investigate the responsiveness to anti-inflammatory glucocorticoid treatment, mice from both 
OVA/alum and OVA/CFA immunized groups received i.p. injections of Dex prior to OVA 
inhalation, and BAL cellular infiltration was examined after 2 OVA challenges [Fig. 2, Suppl. 
Fig. 2A]. In the OVA/alum model, pretreatment with either 1mg/kg or 2.5mg/kg Dex showed a 
potent reduction in infiltrated eosinophils, neutrophils, recruited (CD11b+ autofluomed) AM, DC, 
and CD4 T-cells. In the OVA/CFA model however, 1mg/kg Dex had no effect on cellular 
inflammation while 2.5mg/kg Dex reduced the number of DC and CD4 T cells and to a lesser 
extent of eosinophils, but had no effect on the neutrophil cell count. Thus, using either alum or 
CFA as adjuvants predisposes mice to develop divergent types of pulmonary inflammation that 
are in line with many inflammatory aspects of respectively human eosinophilic and neutrophilic 
asthma types. 
 
2. Lung CD4 T-cell phenotypes 
We characterized the local Th-phenotype generated in the OVA/CFA- and OVA/alum-groups by 
performing RT-qPCR on magnetically purified lung tissue CD4 T-cells [Fig.3A] and by 
flowcytometric phenotyping of interstitial lung lymphocytes after in vitro culture with α-CD3 
[Fig. 3B, Suppl. Fig. 2B]. mRNA expression of the Th-1 transcription factor, T-bet, was induced 
solely in the OVA/CFA model, while its Th-2 counterpart, GATA-3, was slightly induced in 
OVA/alum- and OVA/CFA-mice. mRNA expression of the Th-17 transcription factor, ROR-γt, 
was also induced in both models albeit more prominently in OVA/CFA-mice. Quantification of 
in vitro reactivated lung tissue CD4+ T-cells confirmed this differential Th-phenotype: larger 
IFN-γ+ IL-17- Th-1 and IL-17+ Th-17 CD4+ T cell populations in the lung leukocytes from 
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OVA/CFA compared to OVA/alum, and similar levels in both models of IL-4+ Th-2 CD4+ T cell 
population. 
We also quantified the absolute levels of T-cell-derived or -associated cytokines in the BAL fluid 
by a multiplexed antibody assay [Fig.3C]. Reflecting the higher numbers of BAL T-cells, IL-2 
levels were increased in the OVA/CFA-group. A robust increase in IFN-γ levels, and 
significantly higher presence of IL-12p40 in OVA/CFA-mice compared to OVA/alum-mice 
further confirmed the Th-1-component in the OVA/CFA-model. Importantly, also the levels of 
Th-2 cytokines (IL-4, IL-13 and IL-5) were increased in OVA/CFA, with only IL-5 levels being 
significantly higher in the OVA/alum group. The dramatically increased IL-17 levels in the 
OVA/CFA-group then confirmed the presence of Th-17 cells in this model. Finally, IL-10 levels 
remained unchanged in either group. 
 
3. Innate inflammatory mediator signatures  
We verified to what extent the differential T-cell polarization in OVA/CFA- versus OVA/alum-
conditions reflected at the local inflammatory mediator level. First, we performed RT-qPCR on 
total lung mRNA [Fig.4A]. Reflecting the cellular environment, mRNA expression of Th-1-
chemoattractant (CXCL10) was induced solely in the OVA/CFA-condition, whereas the 
induction of Th-2-and eosinophil-recruiting chemokine (CCL11) was observed only in the 
OVA/alum-group. However, expression of two functionally similar chemokines, Th-1-
chemoattractant CXCL9 and Th-2/eosinophil-recruiting CCL9, were induced in both conditions 
and only showed quantitative differences between both groups. 
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Next, BAL fluid levels of pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) and chemokines 
(CXCL1/KC, CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β and CCL5/RANTES) were analyzed 
by a multiplexed antibody assay [Fig.4B]. This revealed merely quantitative differences in 
inflammatory mediator expression between both groups. Of the cytokines and chemokines 
analyzed, only TNF-α was not induced, whereas the levels of IL-1β, IL-6 and 
monocyte/lymphocyte-attracting chemokines CCL2, CCL3, CCL4 and CCL5 were elevated in 
both groups. Surprisingly, also the levels of the neutrophil chemoattractant, CXCL1, were 
elevated in both groups to a similar extent. Yet, IL-1β, IL-6, CCL4 and CCL5 levels were more 
prominent in the OVA/CFA-mice.  
Next to cytokines and chemokines, we also analyzed the expression levels of additional 
inflammatory mediators. The matrix metalloproteinases, MMP-9 and MMP-12, are thought to 
play detrimental roles in asthma. In line herewith, we observed increased levels of total or 
processed MMP-9 and MMP-12 levels in OVA/alum mice but also in the OVA/CFA model 
[Fig.4C]. Finally, as complement C3a has also been implicated in acute allergic airway 
inflammation, we examined C3a levels in the BAL fluid by ELISA [Fig.4D]. Again, C3a levels 
were elevated in both models, but more prominently so in OVA/CFA-mice. These results show 
that the innate inflammatory mediator signature only partially reflects the differential cellular 
inflammation in the models, with the OVA/CFA-model showing more biomarkers (IL-1β, IL-6, 
C3a) associated with neutrophil-predominant asthma. 
 
4. Genome-wide transcriptome profiling of AM 
AM are long-lived cells residing in the broncho-alveolar cavities that are amongst the first cells to 
encounter inhaled particles and initiate immune responses, and are a common denominator in the 
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BAL immune cell composition of both eosinophil- and neutrophil-dominated asthma. To identify 
(anti-)inflammatory signatures differentially induced by the inflammatory micro-environment in 
AM from neutrophil-dominated versus eosinophil-dominated pulmonary inflammation, we 
performed genome-wide transcriptome profiling of flowcytometric purified CD11chigh 
autofluorescencehigh AM. As shown in Figure 5, both OVA/CFA- and OVA/alum-groups 
exhibited robust changes in the AM transcriptome with over 2800 genes differentially expressed 
in each condition compared to naive AM, a large majority of which was upregulated. Strikingly, 
around 60% of those genes had a concurrent expression pattern, defined as >2-fold up-or 
downregulated in both conditions. Functional clustering of the commonly upregulated gene set 
using online ‘Database for Annotation, Visualization and Integrated Discovery’ (DAVID) 
bioinformatics resources (19) and the ‘Kyoto Encyclopedia of Genes and Genomes’ (KEGG) and 
‘Protein Information Resource’ (PIR) databases, identified mainly inflammation-related 
biological themes, such as cytokine-cytokine receptor interaction, chemotaxis, MHC-II-mediated 
antigen presentation, JAK-STAT signaling and Toll-Like Receptor signaling. Other gene clusters 
(Type-I Diabetes Mellitus, cell adhesion molecules) also comprised genes involved in 
inflammatory signaling and transendothelial migration of inflammatory cells. As apparent from 
Figure 4, genes induced exclusively in the OVA/CFA-condition displayed an overrepresentation 
of immune effector functions, which was absent in genes induced exclusively in the OVA/alum-
group. In the down-regulated gene sets, no inflammation-related biological themes were found 
[Fig.5]. 
 
6. Generic and condition-specific immune effector gene signatures in AM 
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The above clustering analysis of differentially expressed AM genes does not take into account 
quantitative differences in gene expression levels. Therefore, we selected for further analysis an 
immune effector gene set consisting of chemokines, cytokines, growth factors, genes involved in 
arachidonic acid metabolism, and genes involved in antigen processing and presentation. Genes 
having an expression pattern not more than 2-fold different between OVA/CFA and OVA/alum 
versus naïve were assigned to the generic signature. Genes showing 2-fold to 5-fold differences 
in expression between the respective inflammatory conditions versus naïve were assigned to the 
condition-biased signature. Finally, genes over 5-fold differentially expressed between the 
inflammatory models were assigned to the condition-specific signature. The expression levels of 
selected genes were further tested by RT-qPCR for confirmation in an independent repeat 
experiment. The results of this refined transcriptome analysis are shown in Figure 6 and 
discussed in the ensuing paragraphs. 
 
7. Inflammatory mediator differentials 
The majority of differentially expressed (versus naïve) chemo- and cytokines and growth factors 
showed mRNA levels that were identical or similar in OVA/CFA- and OVA/alum-conditions 
[Fig.6A-B], indicating that AM are dedicated to establishing a general pro-inflammatory 
environment and recruiting other leukocytes in both conditions. Importantly, a much smaller 
condition-specific gene set supplemented this generic gene signature. In line with our previous 
results, we found elevated expression of CXCL9, CXCL10 and CCL5 to be part of the 
OVA/CFA-specific gene signature [Fig.6A]. Conversely, the Th-2-/eosinophil-attracting 
chemokines CCL22 and CCL24 but also the neutrophil/monocyte-attracting CXCL7 were part of 
the OVA/alum-specific gene signature. Moreover, we found evidence for immune-modulatory 
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functions of AM. Thus, whereas expression of IL-12b, promoting Th-1 function, was generically 
increased, IL-18 expression, a potent IFN-γ inducing factor acting synergistically with IL-12, was 
repressed [Fig.6B]. Repression of IL-18 activity may be even more pronounced in the 
OVA/CFA-condition, as suggested by the OVA/CFA-specific expression of IL-18BP, a soluble 
IL-18 scavenger. IL18-BP expression may be induced by an endogenous IFN-γ regulated 
feedback loop, present only in the OVA/CFA-condition [Fig.6B]. 
Interestingly, we observed a condition-specific dichotomy in the expression of arachidonic acid-
metabolizing enzymes [Fig.6C]. Arachidonic acid can be metabolized into pro- or anti-
inflammatory eicosanoids. Expression of the pro-inflammatory leukotriene(LT)-synthesizing 
enzymes, Alox5, Lta4h and Ltc4s, was generically repressed. Instead, it appears that the main 
eicosanoids produced in OVA/CFA-AM are anti-inflammatory prostaglandin(PG)E2 and I2 
through Ptgs2, encoding COX2. Conversely, in OVA/alum-AM, expression of Ptgs1, encoding 
COX1, is induced along with a concurrent strong induction of Alox15, suggesting a shift towards 
anti-inflammatory Lipoxin (LX) synthesis. 
 
8. Antigen processing and presentation differentials  
Transcriptome analysis suggested that AM gained increased capacities to interact with T-cells 
and present antigen [Fig.6D]. mRNA expression of CD40, which activates T-cells through 
binding of CD40 ligand, and of ICAM1, which ligates T-cells through LFA-1, were generically 
induced. Increased input of MHC-II molecules into antigen-processing endosomes is suggested 
by induced mRNA expression of MHC-II transcription factor (C2ta), CD74 invariable chain (Ii), 
I-A α-and β-chains (H2-Aa, H2-Ab1), and I-E α-chain (H2-Eb1). Although part of the generic 
gene signature, these genes were invariable higher expressed in the OVA/CFA than in the 
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OVA/alum condition. The OVA/CFA-induced expression of peptide editors (H2-Dmb1, H2-
Dmb2) and their inhibitor (H2-Oa) are then indicative of a broader range of peptides presented in 
this condition. Notably, although expression of the MHC-I common light chain (B2m), TAP 
(Tap1) and TAP binding peptide transporter (Tabp) was generically increased, expression of 
classical MHC-Ia (H2-K1) and non-classical MHC-Ib (H2-M3, Qa-1, Qa-2) genes was biased 
towards the OVA/CFA-condition. Combined, these data indicate that AM-mediated antigen 
presentation to CD4 and certainly to CD8 T-cells may be more effective in OVA/CFA-AM than 
in OVA/alum-AM. The stimulatory versus inhibitory outcome of antigen presentation depends on 
accompanying co-stimulatory signals. Co-stimulatory ICOSL mRNA expression was repressed in 
both conditions whereas CD86 (but not CD80) expression was increased. Yet, also co-inhibitory 
Pdcd1lg2 (encoding for PD-L2) expression was increased in both conditions and further 
supplemented specifically in the OVA/CFA-condition with elevated levels of co-inhibitory 
Cd274 mRNA (encoding for PD-L1).  
 
9. Expression of co-stimulatory molecules on AM and DC 
To confirm these findings at the protein level, we performed flowcytometric analysis of selected 
surface markers on CD11chighautofluorescencemed/high AM as well as 
CD11chighautofluorescencelow DC [Fig.7A-B]. In agreement with the transcriptome analysis, we 
observed moderately elevated surface levels of MHC-II on OVA/alum-AM, and strongly 
elevated levels on OVA/CFA-AM [Fig.7C]. Furthermore, a fraction of these MHC-IIhigh AM also 
was CD40high. Analysis of co-stimulatory CD80 and CD86 as well as co-inhibitory PD-L1 and 
PD-L2 confirmed the findings made at the transcriptome level: in the OVA/CFA-condition, a 
larger fraction of AM were MHC-IIhighCD86high and only few CD80highAM were observed 
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[Fig.7D-E]. Both conditions also showed elevated levels of the co-inhibitory PD-Ls, with PD-L1 
elevated mainly in OVA/CFA-AM and PD-L2 mainly in OVA/alum-AM [Fig.7F-G]. 
Furthermore, in OVA/CFA-AM, expression of PD-L1 coincided with MHC-II expression, 
indicating that especially in this model AM exert a T-cell restraining function.  
Analysis of alveolar DC showed, as expected, a majority of the cells to be MHC-IIhigh CD40high in 
both OVA/CFA-and OVA/alum-conditions [Fig.7C]. Co-stimulatory CD86 expression was more 
pronounced in DC than in AM, especially in the OVA/CFA-model [Fig.7E]. Nonetheless, we 
also observed elevated levels of co-inhibitory PD-L1 and PD-L2, coinciding with elevated MHC-




In this study we addressed the issue of whether mouse models of neutrophil-dominated allergic 
pulmonary and bronchial inflammation could be developed suitable to effectively study the 
cellular and molecular pathways underlying such conditions. In humans, neutrophil-predominant 
asthma forms display some undeniable parallels with HP: neutrophilic infiltration, presence of 
Th-1, Th-17, and Tc cells, and alveolitis (1, 5, 10, 13-18, 21, 25, 28). A classical protocol to 
predispose mice for HP consists of immunization against the actinomycete Saccharopolyspora 
rectivergula in the presence of CFA as Th-1/Th-17-inducing immunogenic co-factor (41). 
Conversely, mice become predisposed to develop features of eosinophil-predominant asthma by 
systemic sensitization with OVA in the presence of the Th-2-skewing adjuvant alum (14). We 
here combined these protocols by sensitizing mice against OVA in the presence of CFA. 
Following OVA inhalation, the resulting pulmonary inflammation featured several cellular and 
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molecular characteristics of neutrophil-predominant asthma: infiltration of lymphocytes, 
neutrophils and macrophages, and polarization of local CD4 T-cells towards Th-1 and Th-17, 
similar to clinical findings (1, 5, 9, 10, 13-15, 28, 42). Importantly, we also observed eosinophilic 
infiltration and evidence of a Th-2-cell component.  
In general, asthmatics with neutrophil- and Th-17-dominated inflammation tend to display an 
increased severity of disease, and both murine and clinical data suggest a relation with steroid 
resistance (1, 32, 42). Indeed, we also found that, whereas Dex treatment dampened 
bronchoalveolar cellular infiltration as well as lung Th-2 numbers (not shown) in OVA/alum 
mice, little to no effect on bronchoalveolar infiltration or lung Th-1, Th-2, and Th-17 numbers 
(not shown) was seen in OVA/CFA mice. From these features, we conclude that this model is 
clinically relevant and appears suitable to study communal aspects of the 
immunopathophysiology of the heterogeneous neutrophilic asthma condition. A previous study, 
in which OVA-induced airway inflammation was elicited by adoptively transferred Th-2 or Th-
17, showed that Th-17 could critically mediate steroid-resistant airway inflammation as well as 
airway hyperresponsiveness (not assessed in this study) in asthma. This hypothesis is 
strengthened by the steroid resistance of inflammation in our OVA/CFA model, in which the 
inflammatory features of neutrophilic and Th-17-dominated asthma may be better represented by 
the additional Th-1 and Th-2 components. Furthermore, extrapolating to clinical asthma, our 
results also indicate that eosinophil- versus neutrophil-dominated or steroid-sensitive versus -
resistant asthma types may divert already at the stage of allergic sensitization, dictated by the 
nature of the immune-modulating danger signaling elicited during sensitization.  
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Comparative analyses of the two models revealed as expected a strong parallel between 
chemokine expression and cellular composition of the inflammatory response. In the OVA/CFA-
model, Th-1-chemoattractants were prominently expressed in contrast with the OVA/alum-
model, where Th-2-/eosinophil-recruiting chemokines predominated. However, protein levels of 
inflammatory mediators in BAL fluid also showed some remarkable resemblances between the 
models. Thus, IL-1β, IL-6, IL-12p40, CXCL-1, α-chemokines and C3a levels were elevated in 
both conditions. This observation, along with the notion that there is redundancy in the 
chemokine and cytokine system (29, 30, 38), could indicate that cytokine measurements in BAL 
as such may not be adequate to distinguish between the different pathologies. It is nonetheless 
interesting to point out the significantly higher levels of C3a, IL-1β, IL-6 and especially IFN-γ in 
the OVA/CFA-mice, since these mediators have been shown to be associated with severe asthma 
attacks (2, 23, 28, 36, 44). Moreover, IL-17 and MMP-9 expression have been correlated with 
asthma severity (3, 9, 12, 31). Although IL-17 was markedly increased in the OVA/CFA-model, 
we found no differences in total and processed MMP-9 in BAL fluid. Also MMP-12 levels and 
proteolytic activity were strongly increased, in line with a previous report showing a role for 
MMP-12 in a model of cockroach-induced neutrophil-dominated asthma (48). However, again 
we found no differences between the models. Thus, although the two experimental models clearly 
represent different pathologies in terms of cellular inflammation, glucocorticoid sensitivity and 
Th-cell phenotypes, the inflammatory micro-environment displays a remarkable number of 
common denominators.  
 
A common constituent in the pulmonary immune cell composition of both eosinophil- and 
neutrophil-predominant asthma are AM. These long-lived cells are presumed to play pivotal roles 
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in the orchestration of local inflammation by producing secreted inflammatory mediators and 
modulating T-cell responses through their antigen-presenting capacities. AM display a 
remarkable plasticity and can be excellent sensors of the inflammatory micro-environment. 
Because of these features, their activation state may reflect distinct inflammatory signatures 
involved in (counter-)acting regulatory checkpoints in neutrophil- or eosinophil-dominated 
allergic disease. Yet, only fragmented and often contradicting information is available on the 
precise functions of AM in asthma (24, 39). We therefore performed a genome-wide 
transcriptome analysis on these cells. A striking first observation was the identification of an 
important generic inflammatory transcriptional program comprising multiple pro-inflammatory 
cytokines, chemokines and growth factors, in line with the common pro-inflammatory 
environment we also observed in the BAL fluid. Genes specifically associated with neutrophilic  
or eosinophilic inflammatory signatures could mostly be linked with differences in BAL cell 
composition (Th1-attracting CXCL9 and CXCL10 in neutrophil- versus Th2-/eosinophil-
recruiting CCL22 and CCL24 in eosinophil-predominant inflammation) or with the earlier 
mentioned notion that the inflammatory setting in the neutrophil-dominated condition possesses 
similarities with severe asthma attacks in clinical disease (higher expression of IFN-γ and IL-6).  
 
Importantly, we found indications that AM may also exert subtle immune-modulatory functions. 
Firstly, we observed a dramatic increase in the mRNA expression of the IL-18 scavenger, IL-
18BP, in the neutrophilic severe asthma-like model. Along with a generic down-regulation of IL-
18, a cytokine that strongly synergizes with IL-12 and the induction of IL-12b mRNA, this result 
indicates that in the neutrophil-predominant asthma model IL-12-driven IFN-γ production by Th-
1 cells is tightly kept in control. Possibly, an endogenous IFN-γ regulated feedback loop (11) 
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underlies this regulatory mechanism. It is tempting to speculate that loss of control at the level of 
the IL-18down/IL-18BPup balance by genetic or environmental factors, resulting in increased IL-18 
activity, may contribute to a shift from eosinophil- to neutrophil-predominant asthma and for 
neutrophil-predominant asthma lead to exacerbation of pathology and lung damage. A second 
(anti-)inflammatory checkpoint is suggested by the strongly polarized mRNA levels of AM 
arachidonic acid-metabolizing key-enzymes: in eosinophilic allergic inflammation a pronounced 
upregulation of Alox15 and Ptgs1 is observed as opposed to the increased expression of Ptgs2 in 
neutrophil-dominated inflammation. A shift towards LX production through Alox15 in 
eosinophilic asthma has been associated with anti-inflammatory activity, as specifically LXA4 
was shown to have beneficial effects in mouse models (4, 7, 27). Conversely, in AM from the 
neutrophil-dominated inflammation model, a shift towards chiefly prostanoid production is 
suggested by the increased expression of Ptgs2. COX2 (encoded by Ptgs2) has a higher affinity 
for arachidonic acid than COX1 (encoded by Ptgs1) (34) and preferentially synthesizes PGE2 and 
PGI2 (8). The role of these two prostanoids in clinical asthma sub-phenotypes is elusive (26), but 
in the allergically inflamed lung PGE2 and PGI2 are considered as anti-inflammatory agents (35, 
46). Thus, it appears that there exists a dichotomy in the AM arachidonic acid metabolism by 
which these cells attempt to control different types of inflammation. Clearly, more studies are 
required to confirm whether the differential Ptgs2 versus Ptgs1/Alox15 pathways in AM could be 
a discriminative feature of neutrophil versus eosinophil asthma types respectively. 
 
Finally, transcriptome and flowcytometric analyses also provided clues as to how AM may 
directly modulate local T-cell functions in an antigen-dependent manner. Especially in the 
neutrophil-predominant condition, an increased capability to exert MHC-I and MHC-II mediated 
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antigen presentation is apparent; increased expression of genes involved in T-cell communication 
(Cd40), antigen processing (B2m, Tap1, Tapbp, C2ta, H2-Dmb1, H2-Dmb2, H2-Oa) and 
presentation (H2-M3, Qa-1, Qa-2, Ii, H2-Aa, H2-Ab1, H2-Eb1) supports this. However, the 
outcome of antigen recognition by local T-cells may be attenuation rather than activation. Thus, 
we observed a dominant expression of co-inhibitory (Cd274 and Pdcd1lg2) over co-stimulatory 
(Cd80, Cd86, and Icosl) ligands. The gene products of Cd274 and Pdcd1lg2, respectively PD-L1 
and PD-L2, have been reported to counteract established Th1- and Th2-mediated immune 
responses and to induce immunological tolerance (22, 40). Flowcytometric analysis of AM 
further supported this proposition. In the neutrophil-predominant condition, MHC-II surface 
levels were clearly upregulated, indicating enhanced antigen presentation capacities. Likewise, 
co-inhibitory PD-L1 levels were strongly increased in the total AM population. In contrast, AM 
from the eosinophilic condition showed only little up-regulation of MHC-II. As expected, DC 
showed all characteristics of potent APC - strongly increased surface levels of CD40, MHC-II 
and CD86 – in either model, but again in the neutrophilic model a bias towards T-cell attenuation 
is indicated by the selective increase of PD-L1. 
 
In conclusion, in this study we established a CFA-based mouse model mimicking the 
inflammatory and glucocorticoid-resistant component of neutrophil-predominant asthma.  
Moreover, our results demonstrate the crucial role of immune potentiating factors present during 
allergic sensitization in determining the nature of the ensuing bronchial allergic response. 
Furthermore, we identified distinctive endogenous regulatory checkpoints superimposed onto a 
generic inflammatory environment potentially controlling the observed phenotype. These 
findings underscore the clinical relevance of comparative studies using the here documented 
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OVA/CFA-based model of neutrophilic allergic inflammation as a counterpart for the 
conventional OVA/alum-based model of eosinophilic allergic inflammation. Mechanistic studies 
addressing the identified anti-inflammatory balances - tight control of IL-12/IL-18 activity, 
prostanoids-biased arachidonic acid metabolism, and local T-cell attenuation - may lead to new 
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Legends to the figures 
Figure 1. Characterization of pulmonary immune cell populations in mice exposed to OVA 
aerosols after systemic sensitization against OVA in the presence of either CFA (OVA/CFA) or 
alum (OVA/alum), and control (naïve) mice (n=6). (A) Average BAL cell count ± SE. (B) 
Average BAL cellular composition ± SE, determined by flowcytometric enumeration of 
eosinophils (CD3ε/B220- I-Ab- CD11c- CCR3+ SSChi), neutrophils (CD3ε/B220- I-Ab- CD11c- 
CCR3- SSCmed), AM (CD3ε/B220- I-Abmed/hi CD11c+ autofluohi), DC (CD3ε/B220- I-Abhi 
CD11c+ autofluolo) and lymphocytes (CD3ε/B220+ CD11c-). (C) Microscopic evaluation of 
pulmonary inflammation in peribronchiolar and interstitial regions on H&E stained sections of 
lavaged lungs. *: p<0.05, **: p<0.01, ***: p<0.001, N.S.: not significant. 
 
Figure 2. Characterization of BAL immune cell populations in (A) OVA/alum and (B) 
OVA/CFA mice, treated with 0, 1, or 2.5mg/kg of Dex (i.p.) 3h prior to OVA challenge 
(n=7/group). Average BAL cellular composition ± SE, determined by flowcytometric analysis of 
eosinophils (CD3ε- I-Ab- CD11c- CD11bmed CCR3+ SSChi), neutrophils (CD3ε- I-Ab- CD11c- 
CD11bhi CCR3- SSCmed), resident AM (CD3ε- I-Abmed/hi CD11blo CD11c+ autofluohi), recruited 
AM (CD3ε- I-Abmed/hi CD11b+ CD11c+ autofluomed), DC (CD3ε- I-Abhi CD11c+ autofluolo) and 
CD4 T-cells (CD3ε+ CD4+ CD11c-). *: p<0.05, **: p<0.01, ***: p<0.001, N.S.: not significant. 
Gating strategy is provided in Suppl. Fig. 2A. 
 
Figure 3. Characterization of local pulmonary T-cell populations in OVA/CFA, OVA/alum and 
naïve mice. (A) Relative mRNA expression levels ± SD of Th-1 (T-bet), Th-2 (Gata3), and Th-
17 (Rorgt) associated transcription factors in purified pulmonary CD4 T-cells, pooled from 5 
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(OVA/CFA, OVA/alum) or 10 (naïve) mice/group. (B) Average levels ± SD of pulmonary Th 
populations in lung leukocytes (pooled from 6 mice/group) after in vitro α-CD3 re-activation, 
determined by flowcytometric analysis of Th-1 (CD45+ CD4+ I-Ab/F4/80- IL-17- IFN-γ+), Th-2 
(CD45+ CD4+ I-Ab/F4/80- IL-4+) and Th-17 (CD45+ CD4+ I-Ab/F4/80- IL-17+). Gating strategy 
is provided in Suppl. Fig. 2B. (C) Average BAL fluid levels of T-cell associated cytokines ± SE 
(n=4/group). *: p<0.05, **: p<0.01, ***: p<0.001, N.S.: not significant.  
 
Figure 4.  Characterization of local innate inflammatory mediator signatures in naïve, OVA/CFA 
and OVA/alum mice. (A) mRNA expression levels ± SD of Th-1-recruiting (Cxcl9, Cxcl10) and 
Th2/eosinophil-recruiting (Ccl9, Ccl11) chemokines in lungs, pooled from 5 mice/group. (B) 
Average BAL fluid levels ± SE of inflammatory cytokines and chemokines (n=4/group). (C) 
Average BAL fluid levels ± SE of total and active MMP-9 and MMP-12 (n=5) and (D) 
complement C3a (n=5).  *: p<0.05, **: p<0.01, ***: p<0.001, N.S.: not significant. 
 
Figure 5. Identification of common and condition-specific over- and underrepresented biological 
themes in the AM transcriptome by genome-wide transcriptome profiling of pooled AM, isolated 
from 10 (OVA/CFA, OVA/alum) or 15 (naïve) mice/group. Transcripts, more than 2-fold 
differentially expressed in OVA/CFA and/or OVA/alum versus naïve condition were withheld for 
unbiased in silico functional clustering analysis. Shown are n-fold enrichment of genes within 
each biological theme, and its p-value (Expression Analysis Systematic Explorer or EASE score). 
EASE < 1.10-4 was considered significantly over- or underrepresented. 
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Figure 6. Selection of generic, condition-biased and condition-specific genes from the genome-
wide transcriptome data set. Selected genes comprise (A) chemokines, (B) cytokines and growth 
factors, (C) arachidonic acid metabolites, and (D) genes involved in antigen processing and 
presentation. Shown are scatter plots of gene transcript expression ratios in either OVA/CFA 
condition vs. naïve (Y-axis) or OVA/alum condition vs. naïve (X-axis), and their classification 
into ‘generic’ (≤ 2-fold differences between OVA/CFA and OVA/alum vs. naïve), ‘condition-
biased’ (> 2- and ≤ 5-fold differences between OVA/CFA and OVA/alum vs. naïve) or 
‘condition-specific’ (> 5-fold differences between OVA/CFA and OVA/alum vs. naïve) 
signatures. √ indicates the induction levels of genes which were tested and confirmed by RT-
qPCR in a biologically independent repeat experiment.  
 
Figure 7. Surface expression of AM and DC ligands involved in antigen presentation and T-cell 
interaction. (A) Flowcytometric discrimination of AM and DC based on autofluorescence and 
surface expression of CD11c. Gating strategy was based on Vermaelen et al., Cytometry, 2004 
(43). (B-G) Flowcytometric analysis of co-stimulatory surface markers on AM and DC from 
OVA/CFA and OVA/alum vs. naïve condition (gated within high autofluorescent/CD11c+ cell 
populations for AM and low autofluorescent/CD11c+ cell populations for the DC). Results were 
obtained by analyzing pooled BAL cells from 8 mice/group. Data shown are representative of 2 
biologically independent experiments. (B) n-fold induction levels of median fluorescence 
intensities. (C-G) Surface expression of CD40, CD80, CD86, PD-L1 and PD-L2 in relation to 
MHC-II expression on AM and DC in the 3 conditions. 
 
Suppl Figure 1. PCR Primers, used in this manuscript 
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Suppl Figure 2. Flowcytometric gating strategies, used in this manuscript. (A) BAL immune cell 
phenotyping based on cellular autofluorescence, side scatter and surface expression of CD3ε, 
CD4, MHCII (I-Ab), CD11c, CD11b and CCR3. Eosinophils are CD3ε- I-Ab- CD11c- CD11bmed 
CCR3+ SSChi, neutrophils are CD3ε- I-Ab- CD11c- CD11bhi CCR3- SSCmed, resident AM are 
CD3ε- I-Abmed/hi CD11blo CD11c+ autofluohi, recruited AM are CD3ε- I-Abmed/hi CD11b+ CD11c+ 
autofluomed, DC  are CD3ε- I-Abhi CD11c+ autofluolo and CD4 T-cells are CD3ε+ CD4+ CD11c-. 
Note: Some CD11c+ cells in this Figure appear false positive for CD3ε because of 
autofluorescence in the CD3ε channel (FITC). (B) Pulmonary Th-1/Th-2/Th-17 phenotyping 
based on surface expression of CD45, CD4, MHC-II (I-Ab), F4/80, and intracellular expression 
of IL-17, IFN-γ, and IL-4. Lung leukocytes were identified as CD45+, and a dump channel for I-
Ab+ or F4/80+ cells was used to get rid of B cells, DC and AM. CD4 T-cells were thus identified 
as CD45+ CD4+ I-Ab/F4/80-. IL-17 positivity was used first to identify Th-17 because these cells 
may also express IFN-γ. Th-1 and Th-2 were then identified as IL-17- IL-4- IFN-γ+ resp. IL-17- 
IL-4+ IFN-γ-. Positivity for intracellular cytokines was defined as signal above isotype control. 






















































































































































eosino neutro resid. AM recr. AM DC





















































































































































































































(C) BAL fluid MMPs (D) BAL fluid C3a

































































































































CATEGORY TERM N-FOLD P-VALUE
ENRICHMENT (EASE)
KEGG Cytokine-cytokine receptor interaction 2.49 2.99E-10 2.28 4.45E-5
SP_PIR Inflammatory response 4.74 2.24E-9
SP_PIR Inflammation 9.77 2.86E-9
SP_PIR Cytokine 2.83 1.45E-7 3.40 3.02E-7
SP_PIR Chemotaxis 4.55 1.78E-7
SP_PIR Phosphoprotein 1.26 2.23E-7
KEGG Antigen processing and presentation 3.35 2.35E-7 6.07 1.17E-13
SP_PIR Transmembrane protein 2.07 3.48E-7
KEGG Type I diabetes mellitus 3.77 4.33E-7 4.41 9.75E-6
SP_PIR Alternative splicing 1.28 1.01E-6 1.27 2.54E-4
KEGG Cell adhesion molecules 2.51 2.74E-6
SP_PIR Heterodimer 4.36 1.01E-5
SP_PIR Mhc ii 10.35 1.64E-5
SP_PIR Direct protein sequencing 1.47 2.37E-5
SP_PIR Immune response 2.62 2.41E-5 3.65 5.42E-7
KEGG Hematopoietic cell lineage 2.77 3.70E-5
KEGG Jak-STAT signaling pathway 2.18 9.15E-5 2.51 2.81E-4
SP_PIR SH3 domain 2.20 1.18E-4
SP_PIR Immunoglobulin domain 1.82 1.66E-4 2.01 1.78E-4
KEGG Toll-like receptor signaling pathway 2.42 1.86E-4 3.49 4.79E-6
KEGG Ubiquitin mediated proteolysis 2.23 2.20E-4
KEGG T cell receptor signaling pathway 2.42 2.70E-4 2.75 5.36E-4
SP_PIR Cytoplasm 1.24 8.60E-4
KEGG Natural killer cell mediated cytotoxicity 4.45 6.16E-12
SP_PIR Antiviral defense 12.02 2.67E-12
KEGG Regulation of autophagy 7.45 2.00E-7
SP_PIR Hydrolase 1.64 2.10E-6
SP_PIR Apoptosis 2.21 4.21E-4
SP_PIR Proteasome 4.39 3.82E-4
SP_PIR Innate immunity 4.65 2.42E-4
SP_PIR Protease 1.92 1.48E-4
SP_PIR Allosteric enzyme 6.89 1.09E-4
SP_PIR Heterotetramer 5.12 2.80E-4
SP_PIR Ubl conjugation 2.09 1.94E-4
CATEGORY
SP_PIR Membrane 1.25 1.48E-5
KEGG Pentose and glucuronate interconversions 9.06 1.45E-5 11.68 2.64E-6
KEGG Androgen and estrogen metabolism 4.39 7.95E-4 5.67 1.39E-4
KEGG Starch and sucrose metabolism 4.02 6.75E-4
SP_PIR Transmembrane 1.27 6.10E-4
SP_PIR Phosphoprotein 1.33 6.27E-61.41 2.29E-6
SP_PIR Fatty acid metabolism 6.07 9.48E-4
KEGG Porphyrin and chlorophyll metabolism 6.25 7.02E-4
SP_PIR Cell cycle 2.42 2.78E-5
GENES, MORE THAN 2-FOLD UPREGULATED COMPARED TO NAIVE CONDITION
COMMON (1508 genes) UNIQUE OVA/alum (970 genes)UNIQUE OVA/CFA (836 genes)
GENES, MORE THAN 2-FOLD DOWNREGULATED COMPARED TO NAIVE CONDITION














Aloxe3 e-LOX-3; Lipoxygenase 3
Lta4h Leukotriene A4 hydrolase
Ltc4s Leukotriene C4 synthase
Ptgs1 COX1: cyclooxygenase 1
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Tapbp tapasin; TAP binding protein
H2-K1 H2-K (murine HLA-A1)
H2-M3 Hmt (murine HLA-F)
Qa-1 H2-T23 (murine HLA-E)
Qa-2 H2-Q8 (murine HLA-G)
C2ta Class II transactivator
Ii Ia-; CLIP; CD74
H2-Aa I-A; Ia-1 (murine HLA-DQ1)
H2-Ab1 I-A; Ia-2 (murine HLA-DQ1)
H2-Eb1 I-E; Ia-4 (murine HLA-C)
H2-Dmb1 H2-M1 (murine HLA-DM)
H2-Dmb2 H2-M2 (murine HLA-DM)
H2-Oa H2-0 (murine HLA-DO)
Icam1 CD54
Cd40 CD40 antigen; Tnfrsf5
Cd86 CD86 antigen; B7-2
Icosl ICOS ligand; B7-H2
Cd274 PD-L1; B7-H1
Pdcd1lg2 PD-L2; B7-DC
MHC Class I antigen presentation
MHC Class II antigen presentation
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     n-fold induction OVA/alum vs naive
GENE GENE PRODUCT Q-PCR
(B) cytokine & growth factor mRNA expression
(D) antigen processing & presentation molecule mRNA expression(C) arachidonic acid metabolizing enzyme mRNA expression
CONFIRM.
GENE GENE PRODUCT Q-PCR
CONFIRM.
GENE GENE PRODUCT Q-PCR
CONFIRM.
GENE GENE PRODUCT Q-PCR
CONFIRM.
B2m
















































OVA/alum - AM OVA/alum - DC


































































































(C) CD40 vs MHC-II












NAIVE - total BAL
AMDC
OVA/alum - total BAL







































































MHC-II [FL3] MHC-II [FL3]
NAIVE - AM NAIVE - DC





































MHC-II [FL3] MHC-II [FL3]
n-FOLD INDUCTION




















      protein expression
(A) AM vs DC
AMDC
AMDC













































































































MHC-II [FL3] MHC-II [FL3] MHC-II [FL3] MHC-II [FL3]
MHC-II [FL3] MHC-II [FL3] MHC-II [FL3] MHC-II [FL3]
MHC-II [FL3] MHC-II [FL3] MHC-II [FL3] MHC-II [FL3]
MHC-II [FL3] MHC-II [FL3] MHC-II [FL3] MHC-II [FL3]
MHC-II [FL3] MHC-II [FL3] MHC-II [FL3] MHC-II [FL3]
NAIVE - AM NAIVE - DC NAIVE - AM NAIVE - DC
NAIVE - AM NAIVE - DC NAIVE - AM NAIVE - DC
OVA/alum - AM OVA/alum - DC
OVA/alum - AM OVA/alum - DC OVA/alum - AM OVA/alum - DCOVA/alum - AM OVA/alum - DC
OVA/CFA -AM OVA/CFA - DC
OVA/CFA -AM OVA/CFA - DC OVA/CFA -AM OVA/CFA - DCOVA/CFA -AM OVA/CFA - DC
